<DOC>
	<DOCNO>NCT00201734</DOCNO>
	<brief_summary>This study determine maximum tolerate dose triplet combination capecitabine administer combination weekly paclitaxel every four week carboplatin .</brief_summary>
	<brief_title>Capecitabine , Carboplatin Weekly Paclitaxel Patients With Solid Tumors Adenocarcinoma Unknown Primary</brief_title>
	<detailed_description>Rationale : The combination chemotherapy drug paclitaxel carboplatin one common combination regimen use clinical practice cancer . These agent use variety cancer . The current study build previous research treatment schedule administer agent reduce toxicity optimize efficacy . The phase I II portion current study combine paclitaxel carboplatin capecitabine patient . Researchers seek identify high dose capecitabine paclitaxel combination carboplatin patient population , well gather information preliminary efficacy . Purpose : The phase I portion study evaluate maximum tolerate dose capecitabine paclitaxel combination carboplatin patient . The phase II portion study assess objective response rate patient use treatment combination . Toxicities closely measure phase study . Treatment : Patients study give capecitabine , carboplatin , paclitaxel . Capecitabine give oral pill . Carboplatin paclitaxel give intravenous infusion . Treatment drug give four-week cycle . Carboplatin administer day 1 , paclitaxel weekly first 3 week , capecitabine twice daily day 8 21 cycle . No treatment give fourth week treatment cycle . During phase I portion study , patient may receive different dos capecitabine paclitaxel since purpose identify maximum tolerate dose drug combination carboplatin . Once maximum tolerate dose agent identified phase I , phase II portion study begin . Treatments discontinue due disease growth unacceptable side effect . Several test exams give throughout study closely monitor patient .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria Phase I : All advance solid malignancy Any prior chemotherapy permit Performance Status 02 Inclusion Criteria Phase II : Adenocarcinoma unknown primary No prior chemo permit Performance Status 02</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
</DOC>